eEF2K-Mediated Stabilization of PCBP2 Promotes Oncogenic mRNA Programs in Triple-Negative Breast Cancer
International Journal of Biological Sciences · 25.03.2026 · 22 (7) · 3714-3730
DOI: 10.7150/ijbs.127111 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 25.03.2026. Verfasst von Yueying Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Triple Negative Breast Neoplasms, Elongation Factor 2 Kinase, RNA, Messenger. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC), characterized by the absence of effective therapeutic targets, remains a major clinical challenge with poor prognosis. The identification of novel molecular targets is therefore crucial for developing effective treatment strategies. Eukaryotic elongation factor 2 kinase (eEF2K) is highly expressed in TNBC and known to promote tumor progression; however, the precise mechanisms underlying its oncogenic role remain elusive. In this study, we identified poly(rC)-binding protein 2 (PCBP2) as a previously unrecognized downstream substrate of eEF2K. Analysis of clinical TNBC specimens revealed a positive correlation between eEF2K and PCBP2 protein expression levels. Further studies demonstrated that site-specific phosphorylation of PCBP2 at serine 189 (Ser189) markedly promoted the malignant phenotype of TNBC cells. Mechanistically, eEF2K-mediated phosphorylation at Ser189 stabilized PCBP2 by preventing its ubiquitin-proteasome-dependent degradation. This phosphorylation-dependent stabilization, in turn, enabled PCBP2 to promote the mRNA stability of pro-oncogenic genes, including TNC, SOX5, and ITGB3, thereby driving TNBC progression. Collectively, these findings not only reveal PCBP2 as a critical downstream effector of eEF2K, but also highlight the eEF2K-PCBP2 signaling axis as a promising therapeutic target for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
- Department of Medical Administration, The Second Hospital of Shandong University, Jinan, 250033, China.
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
- Information and Network Center, Central South University, Changsha 410083, China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zitieren
APA
Cheng, Y., Jiang, T., Zhu, W., He, L., Chen, Z., Li, H., Zhao, R., Jiang, S., & Cheng, Y. (2026). eEF2K-Mediated Stabilization of PCBP2 Promotes Oncogenic mRNA Programs in Triple-Negative Breast Cancer. International Journal of Biological Sciences, 22(7), 3714-3730. https://doi.org/10.7150/ijbs.127111
Vancouver
Cheng Y, Jiang T, Zhu W, He L, Chen Z, Li H, et al. eEF2K-Mediated Stabilization of PCBP2 Promotes Oncogenic mRNA Programs in Triple-Negative Breast Cancer. International Journal of Biological Sciences. 2026;22(7):3714-3730. doi:10.7150/ijbs.127111
BibTeX
@article{Cheng2026,
author = {Cheng, Yueying and Jiang, Ting and Zhu, Wenqian and He, Linhao and Chen, Zongling and Li, Hang and Zhao, Ruigang and Jiang, Shilong and Cheng, Yan},
title = {eEF2K-Mediated Stabilization of PCBP2 Promotes Oncogenic mRNA Programs in Triple-Negative Breast Cancer},
journal = {International Journal of Biological Sciences},
year = {2026},
volume = {22},
number = {7},
pages = {3714--3730},
doi = {10.7150/ijbs.127111}
}
EUVIMED